Only orderable within the Cytogenetics Orders Powerplan.
Collect
Bone marrow, Bone core, or Neoplastic blood; Green Na Heparin
Preferred Draw Volume
1-3 mL bone marrow; bone core; 3-5 mL neoplastic blood
Minimum Draw Volume
1 mL
Unacceptable Conditions
Bone marrow, blood or bone core specimens that are more than 3-4 days old, do not meet volume requirements, are clotted, collected in incorrect containers, frozen or on ice, or lacking identifying information on the tube may be rejected.
Collection Comments
Bone marrow, bone core or neoplastic blood in a sodium heparin tube.
Storage/Transport Temperature
Room Temperature
Stability (from collection to initiation)
Specimen should be received in the IU Cytogenetics Lab within 24 hours of collection if possible. Ambient temperature 48 hours.
Ordering Recommendations
This probe set is intended for use with patients with myeloproliferative disorders.
Performed
Monday-Friday; Days
Methodology
Fluorescence in-situ hybridization (FISH)
Reported
3-5 days
Performing Lab
IU Cytogenetics Laboratory
Synonyms
11488
CPT Codes
88237, 88271 (x3), 88275
Test Code (Outreach Synonym)
11488
Catalog Code
8388827835
Collection
Test Information
Only orderable within the Cytogenetics Orders Powerplan.
Collect
Bone marrow, Bone core, or Neoplastic blood; Green Na Heparin
Preferred Draw Volume
1-3 mL bone marrow; bone core; 3-5 mL neoplastic blood
Minimum Draw Volume
1 mL
Unacceptable Conditions
Bone marrow, blood or bone core specimens that are more than 3-4 days old, do not meet volume requirements, are clotted, collected in incorrect containers, frozen or on ice, or lacking identifying information on the tube may be rejected.
Collection Comments
Bone marrow, bone core or neoplastic blood in a sodium heparin tube.
Storage/Transport Temperature
Room Temperature
Stability (from collection to initiation)
Specimen should be received in the IU Cytogenetics Lab within 24 hours of collection if possible. Ambient temperature 48 hours.
Ordering
Ordering Recommendations
This probe set is intended for use with patients with myeloproliferative disorders.
